(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/140478 A1

(51) International Patent Classification:
A61K 31/502 (2006.01) *A61P 35/00* (2006.01)
A61K 31/5025 (2006.01)

(21) International Application Number:
PCT/IB2021/050122

(22) International Filing Date:
08 January 2021 (08.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/958,792 09 January 2020 (09.01.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Sodertalje (SE).

(72) Inventors: **HATTERSLEY, Maureen**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilimington, Delaware 19850-5437 (US). **PAGEAU POULIOT, Gayle**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **CHEN, Huawei Raymond**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **DE VITA, Serena**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US).


(74) Agent: **LEESE, Mathew**; c/o AstraZeneca Intellectual Property, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMBINATION THERAPY FOR TREATING CANCER

FIG. 1



(57) **Abstract:** The present disclosure relates, in general, to therapeutic combinations of (3*R*)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one and olaparib, and to corresponding methods of treatment, pharmaceutical compositions, and kits.

WO 2021/140478 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*